Products Categories
CAS No.: | 54143-56-5 |
---|---|
Name: | FLECAINIDE ACETATE |
Article Data: | 5 |
Molecular Structure: | |
Formula: | C19H24F6N2O5 |
Molecular Weight: | 474.4 |
Synonyms: | R-818;2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidinylmethyl)benzamide acetate;Flecainide acetate;N-(2-Piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate;54143-55-4;FLECAINIDE MONOACETATE;R 818;Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate;Tambocor;Flecainide acetate [USAN:JAN];Benzamide,N-(2-piperidinylmethyl)-2,5-bis(2,- 2,2-trifluoroethoxy)-,monoacetate;N-(Piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate;Tambocor (TN);acetic acid; N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide;Flecainide acetate (JAN/USP);? Flecainide acetate; |
EINECS: | 258-997-5 |
Density: | 1.286 g/cm3 |
Melting Point: | 145-147℃ |
Boiling Point: | 434.9 °C at 760 mmHg |
Flash Point: | 216.8 °C |
Solubility: | Soluble in dilute acetic acid, dimethyl sulfoxide, ethanol, methanol and water. |
Hazard Symbols: | Xn |
Risk Codes: | 22-36/37/38-63 |
Safety: | 22-26-36/37/39-45 |
PSA: | 96.89000 |
LogP: | 4.25130 |
The Flecainide acetate, with the CAS registry number 54143-56-5, is also known as 2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidinylmethyl)benzamide acetate. It belongs to the product category of Organics. Its EINECS registry number is 258-997-5. This chemical's molecular formula is C19H24F6N2O5 and molecular weight is 474.39. Its IUPAC name is called acetic acid; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide. This chemical's classification codes are Cardiac Depressant (anti-arrhythmic); Human Data; Reproductive Effect. Flecainide acetate is a class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias. It is used to treat a variety of cardiac arrhythmias including paroxysmal atrial fibrillation, paroxysmal supraventricular tachycardia, and ventricular tachycardia.
Physical properties of Flecainide acetate: (1)ACD/LogP: 2.90; (2)ACD/LogD (pH 5.5): -0.19; (3)ACD/LogD (pH 7.4): 0.19; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1.76; (8)#H bond acceptors: 5; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 7; (11)Flash Point: 216.8 °C; (12)Enthalpy of Vaporization: 69.11 kJ/mol; (13)Boiling Point: 434.9 °C at 760 mmHg; (14)Vapour Pressure: 9.11E-08 mmHg at 25°C.
When you are using this chemical, please be cautious about it as the following:
This chemical may cause damage to health. It is harmful if swallowed. In addition, it is irritating to eyes, respiratory system and skin. You should not breathe its dust. Whenever you will contact it, please wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)C.FC(F)(F)COc2cc(C(=O)NCC1NCCCC1)c(OCC(F)(F)F)cc2
(2)InChI: InChI=1/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)
(3)InChIKey: RKXNZRPQSOPPRN-UHFFFAOYAP
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | 50mg/kg (50mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 33, Pg. 2427, 1991. | |
dog | LDLo | unreported | 15mg/kg (15mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 1714, 1999. |
man | LDLo | multiple routes | 25mg/kg/1W-I (25mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | American Journal of Cardiology. Vol. 53, Pg. 329, 1984. |
man | LDLo | oral | 22989ug/kg (22.989mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION | Forensic Science International. Vol. 106, Pg. 115, 1999. |
man | TDLo | intravenous | 1714ug/kg/4M- (1.714mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | American Heart Journal. Vol. 107, Pg. 222, 1984. |
man | TDLo | multiple routes | 26mg/kg/89H-I (26mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Postgraduate Medical Journal. Vol. 62, Pg. 61, 1986. |
man | TDLo | oral | 40mg/kg/2W-I (40mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | Annals of Internal Medicine. Vol. 111, Pg. 107, 1989. |
mouse | LD50 | intravenous | 23800ug/kg (23.8mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991. | |
mouse | LD50 | oral | 170mg/kg (170mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991. | |
mouse | LD50 | subcutaneous | 188mg/kg (188mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991. | |
rat | LD50 | intravenous | 16200ug/kg (16.2mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991. | |
rat | LD50 | oral | 1346mg/kg (1346mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991. | |
rat | LD50 | subcutaneous | 215mg/kg (215mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991. | |
women | TDLo | oral | 20mg/kg (20mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | American Journal of Emergency Medicine. Vol. 16, Pg. 534, 1998. |
women | TDLo | oral | 28mg/kg/1W-I (28mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE | British Medical Journal. Vol. 291, Pg. 450, 1985. |
women | TDLo | oral | 40mg/kg (40mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | British Journal of Clinical Practice. Vol. 49, Pg. 218, 1995. |
women | TDLo | oral | 50mg/kg (50mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE | Connectical Medicine. Vol. 54, Pg. 183, 1990. |
women | TDLo | oral | 56mg/kg/1W-I (56mg/kg) | CARDIAC: OTHER CHANGES | American Journal of Cardiology. Vol. 55, Pg. 1643, 1985. |
women | TDLo | oral | 76mg/kg (76mg/kg) | CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | Annals of Internal Medicine. Vol. 106, Pg. 807, 1987. |
women | TDLo | oral | 160mg/kg (160mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: CHANGE IN RATE | Medical Journal of Australia. Vol. 155, Pg. 349, 1991. |